Vinblastine
- Generic Name
- Vinblastine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C46H58N4O9
- CAS Number
- 865-21-4
- Unique Ingredient Identifier
- 5V9KLZ54CY
- Background
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
- Indication
For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
- Associated Conditions
- Advanced Soft Tissue Sarcoma, Autoimmune Hemolytic Anemia, Bladder Cancer, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Letterer-Siwe disease, Metastatic Melanoma, Non-Small Cell Lung Cancer (NSCLC), Advanced Alibert-Bazin syndrome, Advanced Testicular cancer, Histiocytic lymphoma, Refractory Breast cancer
- Associated Therapies
- -
Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease
- Conditions
- Interventions
- First Posted Date
- 2003-11-21
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 405
- Registration Number
- NCT00002561
- Locations
- 🇨🇦
Regional Health Authority B, Zone 2, Saint John, New Brunswick, Canada
🇨🇦Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇬🇧Royal South Hants Hospital, Southampton, United Kingdom
Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1
- Registration Number
- NCT00072215
- Locations
- 🇺🇸
Broward General Medical Center, Fort Lauderdale, Florida, United States
🇺🇸Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸Palm Beach Cancer Institute - West Palm Beach, West Palm Beach, Florida, United States
S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease
- First Posted Date
- 2003-08-28
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 11
- Registration Number
- NCT00005090
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 482
- Registration Number
- NCT00003027
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 432
- Registration Number
- NCT00006237
- Locations
- 🇺🇸
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus, New Britain, Connecticut, United States
🇺🇸Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States
🇺🇸Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 854
- Registration Number
- NCT00003389
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 23
- Registration Number
- NCT00030264
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 50
- Registration Number
- NCT00002715
- Locations
- 🇺🇸
Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 265
- Registration Number
- NCT00024167
- Locations
- 🇺🇸
Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
🇺🇸St. Luke's Regional Medical Center, Sioux City, Iowa, United States
🇺🇸University of Mississippi Cancer Clinic, Jackson, Mississippi, United States
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 306
- Registration Number
- NCT00002855
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.